Challenging the Dogma: Questioning the Role of Anthracyclines in Early Breast Cancer

Faculty:

Stephen E. Jones, MD Kathleen I. Pritchard, MD, FRCPC Dennis J. Slamon, MD, PhD

Learning Objectives

Upon completion of this activity, participants should be able to:

• Discuss clinical trial results using anthracycline-containing regimens vs nonanthracycline-containing regimens
• Describe data supporting the role of HER2 and topoisomerase IIα as predictors of anthracycline-sensitivity in early breast cancer patients
• Cite the historical status of anthracycline treatment as a standard of care for early breast cancer
• Summarize the adverse events associated with anthracycline-containing regimens

Topics covered include:

• Page 1